MUSTANG BIO, INC. Gain (Loss) on Extinguishment of Debt
MUSTANG BIO, INC. (MBIO) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2025-03-28
- MUSTANG BIO, INC. gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- MUSTANG BIO, INC. gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was $0.00.
- MUSTANG BIO, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- MUSTANG BIO, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-09-30 was $0.00.
- MUSTANG BIO, INC. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- MUSTANG BIO, INC. gain (loss) on extinguishment of debt for fiscal 2023 was -$2.80M.
- MUSTANG BIO, INC. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $0.00 10-K · filed 2025-03-28 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | -$2.79M derived: sum of 3 quarters · filed 2025-03-28 | -$2.80M 10-K · filed 2025-03-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$2.79M derived: sum of 2 quarters · filed 2024-11-08 | -$2.80M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | -$2.79M 10-Q · filed 2024-08-13 | -$2.80M 10-Q · filed 2024-08-13 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-11 | $0.00 10-K · filed 2024-03-11 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |